➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Johnson and Johnson
McKinsey
Mallinckrodt
Medtronic

Last Updated: August 4, 2021

DrugPatentWatch Database Preview

Patent: 10,113,000

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,113,000
Title:Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin\'s lymphomas.
Inventor(s): Grillo-Lopez; Antonio J. (South San Francisco, CA)
Assignee: Biogen Inc. (Cambridge, MA)
Application Number:15/225,594
Patent Claims:see list of patent claims

Details for Patent 10,113,000

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22 ⤷  Free Forever Trial Biogen Inc. (Cambridge, MA) 2018-08-11 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22 ⤷  Free Forever Trial Biogen Inc. (Cambridge, MA) 2018-08-11 RX Orphan search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26 ⤷  Free Forever Trial Biogen Inc. (Cambridge, MA) 2018-08-11 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26 ⤷  Free Forever Trial Biogen Inc. (Cambridge, MA) 2018-08-11 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,113,000

Country Patent Number Estimated Expiration
South Africa 200101157 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 0009160 ⤷  Free Forever Trial
United States of America 2003026804 ⤷  Free Forever Trial
United States of America 2003206903 ⤷  Free Forever Trial
United States of America 2008038261 ⤷  Free Forever Trial
United States of America 2012251534 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Colorcon
Mallinckrodt
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.